Difference between revisions of "Michelle Dipp"
(quote on top) |
m (Text replacement - "healthcare industry" to ""healthcare industry"") |
||
| Line 24: | Line 24: | ||
She was selected a [[WEF/Young Global Leaders 2015|Young Global Leader]] by the [[World Economic Forum]] in 2015. | She was selected a [[WEF/Young Global Leaders 2015|Young Global Leader]] by the [[World Economic Forum]] in 2015. | ||
| − | {{QB|We also feel like [[Covid-19]] gave people a renewed sense of faith in healthcare. I think people had a lot of concern with the healthcare industry and a mistrust in [[Big pharma|pharma]] and biotech. I think people realized, “Oh wow, this is really why they spend so much money on research and development.” The fact that we have multiple [[COVID vaccines]] a year later—it’s nothing short of a scientific miracle<ref>https://www.decibio.com/insights/q-a-with-michelle-dipp-co-founder-and-managing-partner-at-biospring-partners</ref>}} | + | {{QB|We also feel like [[Covid-19]] gave people a renewed sense of faith in healthcare. I think people had a lot of concern with the "[[healthcare industry]]" and a mistrust in [[Big pharma|pharma]] and biotech. I think people realized, “Oh wow, this is really why they spend so much money on research and development.” The fact that we have multiple [[COVID vaccines]] a year later—it’s nothing short of a scientific miracle<ref>https://www.decibio.com/insights/q-a-with-michelle-dipp-co-founder-and-managing-partner-at-biospring-partners</ref>}} |
Revision as of 08:15, 12 September 2024
 Michelle Dipp      (scientist, businesswoman) | |
|---|---|
 | |
| Nationality | US |
| Alma mater | Loretto Academy, Oxford University |
| Member of | WEF/Young Global Leaders/2015 |
| Interests | Digital healthcare |
Biotechnology investor. | |
Michelle Dipp is an American scientist, businesswoman, and investor.[1]
She was selected a Young Global Leader by the World Economic Forum in 2015.
We also feel like Covid-19 gave people a renewed sense of faith in healthcare. I think people had a lot of concern with the "healthcare industry" and a mistrust in pharma and biotech. I think people realized, “Oh wow, this is really why they spend so much money on research and development.” The fact that we have multiple COVID vaccines a year later—it’s nothing short of a scientific miracle[2]
Contents
Early life and education
Michelle Dipp was raised in El Paso, Texas.[3] Her mother was a nurse in the ER and her father was a businessman.[4]
Dipp attended Loretto Academy, where she graduated in 1994.[5] She graduated with a bachelor's degree, an M.D., and a Ph.D. in physiology from Oxford University.[4][6]
Career
After graduation, Dipp moved to Boston, Massachusetts. In 2005, she began working at Sirtris Pharmaceuticals, a startup that created drugs that were meant to slow aging and protect against degenerative diseases related to aging. The company researched and tested activators of sirtuin, such as resveratrol formulations.[3][7] In 2008, she became vice president of corporate development at Sirtris Pharmaceuticals.[4][8]
Sirtris was purchased and made a subsidiary of GlaxoSmithKline in 2008. [9] At GlaxoSmithKline, Dipp became the head of their Center of Excellence for External Drug Discovery.[6]
2008–2010
In 2008, Dipp worked with Christoph Westphal, Richard Aldrich, and Alexey Margolin to found Alnara Pharmaceuticals, which was created to develop ways to formulate biopharmaceuticals so they could be taken by mouth, instead of by injection.[10]
In February 2010, Dipp, Westphal, and Aldrich formed a new venture fund called Longwood Founders Fund. In August 2010, the Longwood team co-founded VeraStem by providing seed funding and office space its offices; Verastem aimed to isolate cancer stem cells and then discover drugs that would selectively kill them. The company held its IPO in 2012.[11]
2015–2020
In January 2015 Longwood and Dipp helped found Flex Pharma[12] In November 2016 Dipp and Longwood helped launch Axial Biotherapeutics where she took a board seat. [13] In October 2017 Dipp became the Managing Director at General Atlantic,[14][12] a global growth equity firm based in New York City. Michelle launched their first life sciences investment platform and served as a member of the life sciences investment committee while at General Atlantic. Michelle served as a Board Observer for Ginkgo BioWorks and as a board member for PathAI and Immunocore.[15]
In 2020, Dipp founded Biospring Partners with Jennifer Lum to conduct venture capital in the life sciences industry. Investments for Biospring Partners include funding for Abzena[16] who were subsequently selected to work on the antibody cocktail for COVID 19 treatment.[17]
Event Participated in
| Event | Start | End | Location(s) | Description |
|---|---|---|---|---|
| WEF/Annual Meeting/2019 | 22 January 2019 | 25 January 2019 | Switzerland World Economic Forum | "The reality is that we are in a Cold War [against China] that threatens to turn into a hot one." |
References
- ↑ https://www.biospring.com/michelle-dipp%7Ctitle=Biospring Partners |
- ↑ https://www.decibio.com/insights/q-a-with-michelle-dipp-co-founder-and-managing-partner-at-biospring-partners
- ↑ a b https://www.elpasotimes.com/story/news/local/el-paso/2016/06/25/el-pasoan-star-biotech-industry/86007726/
- ↑ a b c https://www.elpasotimes.com/story/money/business/2015/09/30/el-paso-native-fortune-40-under-40/73113330/
- ↑ Loretto Academy Alumnae Directory. El Paso, Texas: Harris Connect. 2010. p. 30.
- ↑ a b https://www.bizjournals.com/boston/stories/2009/10/05/focus15.html
- ↑ https://www.nytimes.com/2009/08/18/science/18aging.html?8dpc
- ↑ https://www.fiercebiotech.com/special-report/dr-michelle-dipp-women-biotech-2012
- ↑ https://www.nytimes.com/2008/04/23/business/worldbusiness/23iht-glaxo.1.12262724.html
- ↑ http://www.xconomy.com/boston/2008/10/30/alnara-pharmaceuticals-aims-to-make-biotech-drugs-you-can-swallow-and-go-right-where-they-belong/
- ↑ https://xconomy.com/boston/2013/06/06/verastem-switches-ceos-as-westphal-steps-into-chairman-role/
- ↑ a b https://www.finsmes.com/2017/10/michelle-dipp-joins-general-atlantic-as-managing-director.htm
- ↑ https://www.biospace.com/article/new-boston-biotech-axial-biotech-launches-with-19-15-million-and-will-be-helmed-by-abbvie-glaxosmithkline-vet-
- ↑ https://www.generalatlantic.com/media-article/dr-michelle-dipp-joins-general-atlantic-managing-director/
- ↑ https://www.businesswire.com/news/home/20190417005202/en/PathAI-Secures-60M-in-Series-B-Funding-Led-by-General-Atlantic-and-Existing-Investor-General-Catalyst
- ↑ https://www.wsj.com/articles/biospring-partners-backs-drug-developer-and-manufacturer-abzena-11595891451
- ↑ https://www.pharmoutsourcing.com/1315-News/573005-Abzena-Selected-by-Immunome-to-Manufacture-Antibody-Cocktail-for-COVID-19-Treatment/
This page imported content from Wikipedia on 01.01.2022.Wikipedia is not affiliated with Wikispooks. Original page source here
